Angiostatic cocktail - Angiogen
Latest Information Update: 20 Mar 2014
At a glance
- Originator Angiogen LLC
- Developer Angiogen
- Mechanism of Action Angiogenesis inhibitors; Plasminogen activators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 07 Apr 2006 Phase-I clinical trials in Solid tumours in USA (unspecified route)